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The concept of angiogenic therapy of cancer is based on several
elegant ideas and insights in tumor biology. First, angiogenesis
is absolutely required for tumor growth (Folkman, 1971).
Therefore, inhibition of angiogenesis (antiangiogenic therapy)
can prevent tumor growth (Folkman, 1971, 2003; Hanahan and
Folkman, 1996; Kerbel and Folkman, 2002; Harris, 2002).
Second, due to high proliferative activity, tumor-derived endothe-
lial cells can be targeted selectively. Third, due to low mutation
rate, endothelial cells will be unlikely to acquire drug resistance
associated with an adaptive mutation. In other words, endothelial
cells are resistant to resistance (Kerbel, 1997).
However, an endothelial cell is not the final target of antian-
giogenic therapy. It is the cancer cell, of course, that is the
intended target (Figure 1). By targeting endothelial cells, the
therapy causes hypoxia, which in turn targets cancer cells. Yet,
cancer cells can become resistant to hypoxia (Graeber et al.,
1996;Yu et al., 2002). For example, there is evidence to suggest
that when cancer cells are drug resistant, a tumor is still sensi-
tive to antiangiogenic therapy (Klement et al., 2002). In contrast,
when cancer cells are hypoxia resistant, a tumor is relatively
resistant to antiangiogenic therapy (Yu et al., 2002). By arrest-
ing growth and/or causing death of hypoxia-sensitive cells,
hypoxia selects for apoptosis-resistant and increasingly malig-
nant cells (Graeber et al., 1996; Kim et al., 1997). In agreement,
hypoxia induces benign-to-malignant melanoma progression in
vitro (Stackpole et al., 1994). This seems to be a therapeutic
problem by itself. But to make matters worse, as we will discuss
in the next section, hypoxia activates cancer cells, namely
increases their capability to induce angiogenesis, to invade and
metastasize.
Activation by hypoxia (reactive resistance)
In the presence of oxygen, the α subunit of hypoxia-inducible
factor (HIF) is hydroxylated and binds to VHL, which in turn tar-
gets it for degradation (Ivan et al., 2001; Jaakkola et al., 2001;
Kaelin, 2002; Safran and Kaelin, 2003). Under hypoxia, HIF-1α
is rapidly accumulated, and HIF-1 transactivates hundreds of
genes, including angiogenic and autocrine growth factors and
receptors, glycolitic enzymes, and extracellular proteases
(Semenza, 2000, 2002). In addition, hypoxia inhibits secretion
of antiangiogenic factors, such as thrombospondin-1 (TSP-1),
thus stimulating angiogenesis (Hanahan and Folkman, 1996;
Laderoute et al., 2000), resolving hypoxia (Figure 1). Such a
compensatory hypoxic response may hamper antiangiogenic
therapy (reactive resistance). Angiogenic factors such as vascu-
lar endothelial growth factor (VEGF) and bFGF induce survivin
in endothelial cells and significantly reduce the proapoptotic
potency of chemotherapy on endothelial cells (Tran et al.,
2002). Angiogenic factors, which are produced by cancer cells
in response to hypoxia, may act to shield tumor endothelial 
cells (Tran et al., 2002). By activating hypoxic response in can-
cer cells, antiangiogenic therapy may promote metastasis and
invasion (Bottaro and Liotta, 2003; Pennacchietti et al., 2003;
Steeg, 2003). As emphasized, however, antiangiogenic therapy
has not been shown to induce metastases in the clinic (Kieran
et al., 2003). Yet, current antiangiogenic therapy may not be
effective enough to induce hypoxia in tumors: if therapy does
not effectively cause remissions, it may not promote late metas-
tases either. There is overwhelming evidence that hypoxia, in
theory, must promote metastasis and invasive growth (for refer-
ence, see Hockel and Vaupel, 2001; Blagosklonny, 2001;
Semenza, 2002). First, hypoxia and HIF-1 expression correlate
R E V I E W
Antiangiogenic therapy and tumor progression
Mikhail V. Blagosklonny*
Brander Cancer Research Institute, New York Medical College, 19 Bradhurst Avenue, Hawthorne, New York 10532
*Correspondence: m_blagosklonny@nymc.edu
Angiogenesis is necessary for tumor growth (a rationale for antiangiogenic therapy), but hypoxia caused by such a therapy
will, in theory, drive tumor progression and metastasis.To reconcile conflicting notions, we discuss that, first, although a shift
from normoxia (21% O2) to hypoxia indeed activates cancer cells for aggressive behavior, this may not occur during therapy,
because most cancers are not normoxic to start with. Second, only successful antiangiogenic therapy, which is capable of
controlling cancer, will select for resistance and progression. After all, in order to occur, therapy-induced tumor progression
must be preceded by tumor regression.
Figure 1. Reactive resistance to antiangiogenic therapy
Inhibition of angiogenesis causes hypoxia, which in turn causes HIF-1 stabi-
lization in cancer (and stromal) cells. HIF-1 transactivates angiogenic fac-
tors to stimulate angiogenesis, thus resisting antiangiogenic therapy. In
addition, hypoxia stimulates factors of invasion and metastasis. This hypox-
ic response prevents cancer cell death and may stimulate migration, inva-
sion, and metastasis.
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with metastasis and poor prognosis (Hockel et al., 1999;
Zagzag et al., 2000; Hockel and Vaupel, 2001). Second, follow-
ing exposure to acute hypoxia, cancer cells become highly
tumorigenic and metastatic (Cairns et al., 2001). Third, hypoxia
activates invasive and metastatic characteristics of cancer cells
in vitro. Hypoxia and HIF-1 transactivate genes that are critical
for invasion and metastasis. In hypoxic cancer and stromal cells,
HIF-1 induces autocrine and paracrine growth/survival factors
including VEGF, FGF, adrenomedullin, PAI-1, nitric oxide syn-
thase, cathepsin D, matrix metalloproteinase 2, urokinase plas-
minogen activator receptor (uPAR), fibronectin 1, keratins,
vimentin, transforming growth factor α, and autocrine motility
factor, which are proteins that play established roles in the
pathophysiology of invasion (Garayoa et al., 2000; Rofstad et
al., 2002; Semenza, 2003). For example, neutralizing antibodies
against uPAR block tumor cell invasion induced by hypoxia
(Krishnamachary et al., 2003). Among recent examples, it has
been shown that hypoxia stimulates tumor invasion by activat-
ing hepatocyte growth factor (HGF), resulting in c-met activa-
tion, elevated motility, and invasion (Pennacchietti et al., 2003),
and HIF transcriptionally induces the chemokine receptor
CXCR4, which governs cancer cell metastasis (Staller et al.,
2003). It is well established that shifting cells from normoxia
(21% O2) to hypoxia activates pathways of invasion and metas-
tasis. This suggests that antiangiogenic therapy will activate
cancer cells for invasion, metastasis, and aggressive behavior.
However, the problem with this premise is that normoxia, as
defined above, does not exist. No cell (except for aerobic
microorganisms) lives in air.
From near-hypoxia to deep hypoxia
Normal conditions in vivo are near-hypoxic or hypoxic. This
detail may change our view on fundamental processes such as
cell senescence, for instance. While fibroblasts undergo cell
senescence in “normoxic” (21%) conditions, they are immortal
under conditions of 3% oxygen (Parrinello et al., 2003). And cer-
tain normal cells do not grow in vitro at all.
Typically, experiments testing the effects of hypoxia tend to
compare cells cultured under hypoxia/anoxia (meaning oxygen
levels between 0% and 3% or following chemical anoxia as pro-
duced by DFX and cobalt) versus so-called normoxic conditions
(invariably 21% O2). Yet, “normoxia” defined as 21% oxygen
(160 mm Hg, pO2) is at least 4 times higher than the physiologi-
cal in vivo normoxia. In venous blood, there is an average 40
mm Hg O2, which is a result of equilibrium with oxygen in tis-
sues. And while some tissues have higher than average oxygen
levels, in other tissues (and especially solid tumors), 
oxygen levels are lower than the average. In fact, certain tis-
sues, including cartilage, bone marrow, and placenta, require
hypoxic conditions for their proper function; proliferation of
hematopoietic and placental cells is stimulated by HIF-1 induc-
tion, a consequence of tissue hypoxia (Adelman et al., 1999,
2000; Schipani et al., 2001). Hypoxia is a state that causes a
compensatory response such as the accumulation of HIF-1. In
fact, HIF-1 increases exponentially with decreases in oxygen
such that it is half maximal at O2 concentrations between 1.5
and 2% and maximal at 0.5% O2 (Jiang et al., 1996). In vivo,
even normal cells exist at near-hypoxia. A case in point is the
HIF-1-mediated production of erythropoietin occurring as the
result of even a slight decrease in blood hemoglobin levels
(Semenza and Wang, 1992).
The bottom line is that 21% O2 is not physiological, espe-
cially for tumors where oxygen levels of around 1% (5–10 mm
Hg) are an accepted borderline between well and poorly oxy-
genated tumors (Hockel et al., 1999; Hockel and Vaupel, 2001).
Thus, one could say that even normally oxygenated (>10 mm
Hg) tumors are mostly hypoxic. With this in mind, the overex-
pression of HIF-1 in tumors is likely to mean that tumors almost
always live under hypoxia.
To start with, the metastatic and invasive properties of can-
cer cells are activated by physiological hypoxia. Instead on
inflicting hypoxia, an effective antiangiogenic therapy will shift
hypoxia (the normal oxygen state of tumors) to a deeper hypox-
ia. A response to a shift from hypoxia to anoxia (severe oxygen
depletion) is HIF-1 independent and differs from hypoxic
response (Ameri et al., 2003). In addition, severe oxygen deple-
tion is associated with lack of glucose and other nutrients, starv-
ing cells to death. This is a classic goal of antiangiogenic
therapy (Folkman, 2003). Paradoxically, antiangiogenic therapy
might also increase the efficiency of the tumor vasculature,
increasing the delivery of oxygen and drugs (Hansen-
Algenstaedt et al., 2000; Jain, 2001). By eliminating excess
endothelial cells, the resulting tumor vessels would be more
conductive to the delivery nutrients, oxygen, and drugs. This
explains potentiation of radiation and chemotherapy by antian-
giogenic therapy (Pan et al., 2003). If the goal is to deprive the
tumor of its blood supply, therapy must continue until the vascu-
lature no longer functions (Jain, 2001).
Tumor regression and progression:Two sides of one coin
Almost by definition, an effective therapy must select for cells
resistant to therapy. By killing sensitive cells and sparing mutant
cells that are resistant, therapy selects for resistance. These
resistant cells proliferate, forming a resistant tumor in relapse
(Figure 2, relapse). Only when therapy is not effective, thus
allowing even most sensitive cells to proliferate, is there no
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Figure 2. Antingiogenic therapy from tumor regression to resistance (tumor
progression)
By suppressing proliferation and survival of angiogenesis-dependent can-
cer cells, antiangiogenic therapy causes therapeutic response (remission)
but simultaneously selects for resistant cancer cells.
A: Ineffective therapy causes neither remissions nor resistance.
B: The therapy suppresses most angiogenesis-dependent cancer cells but
spares less sensitive cells. In relapse, a tumor is moderately resistant.
C: Effective therapy suppresses most cancer cells and only a few most
resistant cells survive. Therefore, remission may be deep and curative.
Once relapsed, tumor is hypoxia resistant and aggressive.
D: The most effective therapy suppresses all cancer cells.
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selection for resistance (Figure 2A). So selection for resistance
is a hallmark of an effective therapy and a consequence of tumor
regression. Most importantly, despite selective pressure for
resistance, cancer may never relapse. First, there may be no
cells that are sufficiently resistant to tolerate very effective thera-
py. This (curative) outcome will be likely, when a population of
cancer cells is small and a mutation rate is low (Blagosklonny,
2002). There are several examples of effective therapies. The
Bcr-Abl inhibitor Gleevec selects for resistance, exactly because
it is selective and effective against Bcr-Abl-expressing leukemia.
By killing all leukemia cells that depend on Bcr-Abl, it selects for
cells with mutant or amplified Bcr-Abl and other mechanisms of
resistance (Druker, 2002; Sawyers, 2002). As another example,
tissue-selective therapies of prostate and thyroid cancers with
antiandrogens (Reese, 2000) and radioactive iodine (Pelikan et
al., 1997), respectively, are very selective and effective, causing
clinical responses and remissions. These effective therapies
eventually select for drug resistance, associated with tumor pro-
gression. Once relapsed, hormone-independent prostate cancer
and anaplastic thyroid cancers are most aggressive, therapy
resistant, and lethal cancers (Zietman et al., 1996; Pelikan et al.,
1997). Similarly, antibiotics select for antibiotic-resistant bacte-
ria. Despite this obstacle, antibiotics are very useful in therapy of
bacterial infections. In fact, antibiotics select for resistant bacte-
ria because they kill nonresistant bacteria. In all cases, selection
for resistance cannot occur without therapeutic response or at
least temporal disease regression.
In this light, it is not surprising that an antiangiogenic thera-
py, if effective, will select for resistance. The question is what
exactly will be selected. Overexpression of HIF may help cells to
survive low oxygen and starvation. However, HIF-1 simultane-
ously induces and inhibits apoptosis and proliferation
(Carmeliet et al., 1998; Harris, 2002). For example, HIF-1
induces proapototic BNIP and inhibits cell proliferation by acti-
vating CDK inhibitors (Sowter et al., 2001; Goda et al., 2003).
HIF-2 can mediate apoptosis in low glucose (Brusselmans et
al., 2001). On the other hand, HIF-1 renders pancreatic cancer
cells resistant to apoptosis induced by hypoxia and nutrient
deprivation (Akakura et al., 2001). Cells, lacking HIF-1, may
grow faster than parental cells (Carmeliet et al., 1998). On the
other hand, loss of HIF-1 retards solid tumor growth because of
defective angiogenesis (Ryan et al., 1998; Carmeliet et al.,
1998). Therefore, to provide a selective advantage, there must
be a shift in the balance such that HIF-1 neither induces apop-
tosis nor inhibits growth. In other words, overexpresion of HIF-1
requires the absence of growth inhibitory and proapoptotic
pathways downstream of HIF-1. In aggressive cancers, overex-
pression of HIF-1 is accompanied by loss of p53, insensitivity to
p21, and ability to proliferate in hypoxia (Salnikow et al., 2000).
It could be predicted that selection for cells that can proliferate
in the presence of a constantly elevated HIF-1 can yield cells
lacking restrictions of the cell cycle and apoptotic machinery.
These are hallmarks of malignant cells.
From remission to cure
Thus, response to therapy (inhibition of growth and/or survival
of cancer cells) and selection for resistance will occur simulta-
neously (Figure 2). By inhibiting vessel-dependent cancer cells,
antiangiogenic therapy might be expected to favor cells that
overexpress HIF-1, and lack apoptotic machinery and cell cycle
control. Following an inadequate therapy (Figure 2A), the tumor
will not become resistant. But then therapeutic benefits will be
also minimal. Following an effective therapy, only resistant can-
cer cells will remain. Once relapsed, the tumor will be resistant
(Figure 2C). If only a few cancer cells survive, the relapsed
tumor (if it relapses) will be the most resistant. But there may be
no cells that are sufficiently resistant to tolerate most effective
therapy (Figure 2D).
So what limits antiangiogenic therapy: low efficacy of the
therapy (Figure 2A) or therapy-induced tumor progression
(Figures 2B and 2C)? There is no indication that antiangiogenic
therapy promotes metastasis and progression (Kieran et al.,
2003), but it does not cause remissions either. Therefore, cur-
rent antiangiogenic therapy is limited mainly by the shortage of
selective drugs and their rational combinations that can “starve
the tumor to death.”There are several strategies to increase effi-
cacy of antiangiogenic therapy. Potent VEGF blockade can
cause regression of established tumors and metastases
(Huang et al., 2003). Also, metronomic chemotherapy (continu-
ous low-dose chemotherapy) can be successfully combined
with inhibitors of VEGF or VEGF receptor signaling (Klement et
al., 2000; 2002). A combination of antiendothelial drugs and
anti-HIF drugs is an attractive therapeutic modality. By them-
selves, inhibitors of HIF-1 are a mechanism-based antiangio-
genic therapy, because it is a HIF-mediated response that
drives angiogenesis in the first place. Inhibitors of HIF-1 are cur-
rently under development (Rapisarda et al., 2002; Harris, 2002;
Mabjeesh et al., 2003; Knowles et al., 2003; Semenza, 2003;
Giaccia et al., 2003). For example, geldanamycin, which targets
HIF-1 for degradation (Mabjeesh et al., 2002), synergizes with
the antiangiogenic stress imposed by Id1 loss to lead to a com-
plete remission of aggressive tumors in mice (de Candia et al.,
2003). One can expect that anti-HIF agents will prevent both a
compensatory activation of cancer cells and selection for cells
with an overexpressed HIF-1. In the absence of HIF-1, lack of
oxygen and nutrients will result in acidosis and tissue necrosis;
no tumor cell can be resistant to tissue necrosis. As an addition-
al strategy to exploit hypoxia, antiangiogenic therapy could be
combined with inactive prodrugs, which are activated by hypox-
ia (Dachs et al., 1997; Brown and Giaccia, 1998). For example,
under hypoxic conditions, tirapazamine is reduced to a radical
that leads to DNA double-strand breaks, single-strand breaks,
and base damage (Peters and Brown, 2002). And finally,
instead of inhibition of HIF-1, its overexpression can be exploit-
ed by designing HIF-1-dependent drugs (Sutphin et al., 2004).
Given this variety of potential therapeutic approaches, we can
imagine effective antiangiogenic therapies of the future.
Although hypoxia activates cancer cells for aggressive behavior,
most cancer cells are inherently activated by physiological
hypoxia; and antiangiogenic therapy may not galvanize them
further. Effective therapy will, however, select for resistant and
aggressive cancer cells during therapy-induced tumor regres-
sion. Despite this, following effective therapy, the disease may
not necessarily have a chance to relapse (Figure 2C).
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